LAUSANNE, Switzerland and SAN FRANCISCO, March 9, 2021 /PRNewswire/ — Asceneuron SA, an rising chief within the improvement of remedies for neurodegenerative illnesses, introduced immediately the receipt of a USD 2.2 million award from the Alzheimer’s Drug Discovery Basis (ADDF) for a primary in human Part I examine of the Firm’s subsequent technology O-GlcNAcase inhibitor, ASN51. The trial is because of recruit wholesome volunteers and Alzheimer’s illness sufferers at websites in Europe and Australia, to begin in Q2 2021, with first interim information due in Q3 2021.
The award will assist a Part 1 single ascending dose arm and a positron emission tomography (PET) goal engagement examine in wholesome volunteers. The Part 1 scientific trials will assess security and tolerability of ASN51, and intently study a number of biomarkers related to the goal mechanism and neurodegeneration in wholesome topics and Alzheimer’s sufferers.
O-GlcNAcase is an rising drug goal in central nervous system (CNS) drug improvement since poor glycosylation patterns of intracellular proteins have been related to illnesses of growing old and neuronal dysfunction. O–GlcNAcase inhibitors stop the elimination of intracellular protein glycosylation, thereby halting the decline of the steady-state ranges of this posttranslational modification. O–GlcNAcase inhibitors have initially been pursued solely for tau-related illnesses. Rising preclinical information counsel a wider utility to intracellular proteinopathies similar to Alzheimer’s illness and associated issues, and illnesses of disturbed neuronal community operate normally, with the potential to offer each disease-modifying and symptomatic advantages concurrently multimodal medicine.
Dirk Beher, Chief Government Officer and a Co-Founding father of Asceneuron, commented: “This Part I scientific examine focusing on the foundation reason for neurodegeneration comes at a time when our present data of the biology of O–GlcNAcase has reached a vital inflection level. As a pacesetter on this discipline, and with the welcome assist of ADDF, we plan to translate our novel and thrilling biology into vital well being advantages for sufferers with neurodegenerative illnesses.”
Howard Fillit, M.D., Founding Government Director and Chief Science Officer of the ADDF, commented:
“Alzheimer’s illness is a posh neurodegenerative illness, and plenty of research spotlight the position of lowering neurodegeneration as a promising path to efficient remedy. The ADDF is happy to assist advance Asceneuron’s analysis program to check this drug candidate in Alzheimer’s sufferers in a Part 1 scientific trial.”
Peter Van Vlasselaer, Chairman of Asceneuron added: “We’re delighted to have acquired this substantial recognition from the ADDF for our work in neurodegeneration, and the potential of our pipeline. Along with assist of the ADDF, we glance to remedies for not simply AD, however all and associated dementias, offering new hope for the medical group, the sufferers, and their households / one of many biggest healthcare challenges of our time.”
Asceneuron is a scientific stage biotech firm centered on the event of orally bioavailable therapeutics for debilitating neurodegenerative issues with excessive unmet medical want. The pipeline displays our ambition to develop remedies for as vast a variety of neurodegenerative illnesses together with orphan tauopathies, Alzheimer’s and Parkinson’s illnesses. The lead program ASN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron can be creating a subsequent technology O-GlcNAcase inhibitor ASN51 to focus on Alzheimer’s illness and associated issues.
Asceneuron is a privately held firm financed by a famend syndicate of buyers consisting of Sofinnova Companions, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Companions. For extra info, please go to www.asceneuron.com.
Concerning the Alzheimer’s Drug Discovery Basis (ADDF)
Based in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Basis is devoted to quickly accelerating the invention of medicine to stop, deal with and treatment Alzheimer’s illness. The ADDF is the one public charity solely centered on funding the event of medicine for Alzheimer’s, using a enterprise philanthropy mannequin to assist analysis in academia and the biotech trade. Via the generosity of its donors, the ADDF has awarded greater than $168 million to fund over 650 Alzheimer’s drug discovery and biomarker packages and scientific trials in 19 international locations. To be taught extra, please go to: http://www.alzdiscovery.org/.